Observational Study of Ketamine Infusions for the Treatment of Chronic Pain
Launched by THERESA LII · Jul 25, 2022
Trial Information
Current as of July 25, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Ketamine is a type of anesthetic drug which has been used off-label to treat chronic pain. The effectiveness of intravenous ketamine and its duration of effect are not well-understood. There is high variability in response to ketamine, and it remains unclear which patient characteristics are associated with favorable outcomes. This observational study will collect a wide range of patient-reported outcomes via digital surveys: once at baseline before treatment, and up to 7 follow-up surveys for up to 12 months following a single ketamine infusion. Survey data will be supplemented by clinical...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Has been seen at Stanford's Pain Management Center for a doctor's visit at least once.
- • Is scheduled to undergo at least 1 ketamine infusion for the treatment of any chronic pain condition.
- • Have a valid email address and consents to receiving surveys by email.
- • Able to read, understand, and respond to English-language surveys on an electronic device such as a cell phone, tablet, or computer.
- • Able to read, understand, and provide written, dated informed consent.
- Exclusion Criteria:
- • Has their ketamine infusion cancelled, which may occur before or after consenting to this study.
About Theresa Lii
Theresa Lii is a dedicated clinical trial sponsor committed to advancing medical research and innovation. With a focus on developing novel therapies and improving patient outcomes, the organization collaborates with healthcare professionals and research institutions to conduct rigorous clinical studies. Theresa Lii prioritizes ethical standards and regulatory compliance, ensuring the safety and well-being of participants while striving to bring groundbreaking treatments to market. Through a patient-centered approach and a commitment to scientific excellence, Theresa Lii aims to contribute significantly to the fields of medicine and healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Stanford, California, United States
Patients applied
Trial Officials
Theresa Lii, MD
Principal Investigator
Stanford University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials